Even though next-generation sequencing (NGS) cancer testing has moved from a rarity to a common feature of clinical practice in recent years, reimbursement policies for NGS testing still vary widely among private and public insurers across different countries.
In the United States, both large commercial labs and large health systems offer NGS tumor testing, and it is anticipated that this landscape will change the availability of a US Food and Drug Administration (FDA)-approved NGS tumor panel. Meanwhile, healthcare systems in Europe are taking what is, in many ways, a very different approach to reimbursement of clinical sequencing with NGS. In France, for example, a network of regional laboratories will be reimbursed to provide molecular testing services. Similarly, genomic laboratory hubs will provide access to whole genome sequencing in the UK beginning in 2019.
In this free webinar, the featured speakers will shed light on the clinical and commercial reality of NGS in oncology, with predictions for what lies ahead in the United States and Europe.
Dr. Bruce Quinn, MD, PhD, Principal, Bruce Quinn Associates LLC
Dr. Bruce Quinn is an expert on health reform, innovation and Medicare policy. A pathologist by training, he has worked on a wide range of federal health policy issues ranging from biopharma to genomics. After a career in academic medicine, he became a successful physician executive at Accenture, serving clients in both the biopharma and payer industries. For five years, he was the regional Medicare Medical Director for California, making decisions on a wide range of emerging technologies. Since 2008, he has been a full-time life sciences strategy consultant. From 2008-2017, he worked as an internal strategic asset for the clients of two major law firms, Foley Hoag LLP and Faegre Baker Daniels LLP.
Since 2017, Dr. Quinn manages his own medtech and biopharma consulting practice based in Los Angeles and San Francisco, Bruce Quinn Associates LLC, working collaboratively with a number of Washington-based policy and lobbying groups. Dr. Quinn is a frequent presenter at national conferences on payers and health policy, especially regarding the management of innovation and new technologies in genomics. His blog, Discoveries in Health Policy,currently logs over 100,000 hits per year. Dr. Quinn has helped leading companies in the medical device and genomics spaces negotiate with the Centers for Medicare and Medicaid Services on coding and coverage issues.Message Presenter
Joseph V. Ferrara, President & CEO, Boston Healthcare Associates
Joseph Ferrara has over 20 years of experience in life sciences consulting, working with biopharmaceutical, medical device, diagnostics and healthcare IT clients in market and business development strategy. He leads the global consulting team with practice areas in reimbursement and pricing, health economics, market analysis and business development strategy. Mr. Ferrara has extensive experience in the development of novel business approaches designed to capture evidence-based value for innovative healthcare technologies. Mr. Ferrara writes and speaks extensively on the value of medical technology innovation, with a particular focus on pharmacogenomics, specialty pharmaceuticals and novel therapeutic devices.
Prior to his consulting role, Mr. Ferrara led a joint venture between Boston Healthcare and a non-profit research organization focused on a global electronic medical record network for the purposes of clinical trials and health outcomes research.
Mr. Ferrara completed undergraduate studies at the University of Cincinnati and received a Master’s Degree from Harvard University.Message Presenter
Who Should Attend?
Molecular diagnostic test developers and laboratories working in:
- Market Access
- Business Development
Members of pharmaceutical companies developing oncology and rare disease therapies working in:
- Market Access
- Advocacy/Government Affairs
- Brand Managers
- Business Development
What You Will Learn
Participants will gain insights into:
- An overview of NGS testing in cancer
- Recent policy changes and announcements for NGS coverage, reimbursement and determination
- Predictions for what lies ahead for the industry in the US and EU
Boston Healthcare is a global strategy consulting firm that provides market access and value optimization strategies to healthcare technology and service innovators. We help clients unlock the value of medical devices, diagnostics, biopharmaceuticals, and informatics that have the potential to transform patient care and significantly improve health outcomes.